 LONDON, Nov. 17, 2020 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology ASH Virtual Congress 2020 and will also participate in the Jefferies Banking Conference: 